QuidelOrtho (Nasdaq: QDEL) trims 2026 revenue and EPS guidance
Rhea-AI Filing Summary
QuidelOrtho reported second quarter 2026 results with total revenue of $630.9 million, a 2.8% year-over-year increase, and a GAAP net loss of $92.9 million, or a loss of $1.36 per diluted share. Adjusted EBITDA was $129.3 million, a 20.5% margin, as Labs revenue grew 4% and Point of Care revenue grew 16%.
Revenue excluding China rose 6.1%, while China revenue declined 18.7%, reflecting pressure from proposed In Vitro Diagnostics pricing changes. QuidelOrtho cut its 2026 outlook to $2.52–$2.60 billion in revenue, $540–$560 million in adjusted EBITDA and $0.65–$0.90 adjusted EPS, and withdrew free cash flow guidance after using $143.6 million of operating cash in the first half.
Positive
- None.
Negative
- Full-year 2026 outlook reduced: revenue to $2.52–$2.60 billion from $2.70–$2.75 billion, adjusted EBITDA to $540–$560 million from $615–$630 million, adjusted EPS to $0.65–$0.90 from $1.80–$2.00, and $100–$120 million free cash flow guidance withdrawn.
Filing Explained
The filing records QuidelOrtho’s quarter-end liquidity and borrowing position.
The company furnishes its second-quarter results through this
Form 8-K item numbers identify the event category; here, Item 2.02 covers results of operations and financial condition, while Item 9.01 lists the press release as a furnished Exhibit 99.1.
The filing discloses the company’s quarter-end liquidity and borrowing position.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenue Q2 2026: $630.9 million
GAAP net loss Q2 2026: $92.9 million
Adjusted EBITDA Q2 2026: $129.3 million
+4 more
7 metrics
Total revenue Q2 2026
$630.9 million
Three months ended June 28, 2026; 2.8% increase versus Q2 2025
GAAP net loss Q2 2026
$92.9 million
Net loss for the three months ended June 28, 2026
Adjusted EBITDA Q2 2026
$129.3 million
Adjusted EBITDA for the three months ended June 28, 2026; margin 20.5%
Adjusted diluted EPS Q2 2026
$0.13
Adjusted diluted earnings per share for the three months ended June 28, 2026
Cash used in operating activities H1 2026
$(143.6) million
Cash used for operating activities for the six months ended June 28, 2026
Updated 2026 total revenues guidance
$2.52–$2.60 billion
Full-year 2026 total revenues (reported) guidance as of August 6, 2026
Updated 2026 adjusted diluted EPS guidance
$0.65–$0.90
Full-year 2026 adjusted diluted EPS guidance as of August 6, 2026
Key Terms
adjusted EBITDA, constant currency, In Vitro Diagnostics pricing, non-GAAP financial measures
4 terms
adjusted EBITDA financial
"Adjusted EBITDA was $129 million, with an adjusted EBITDA margin of 20.5%"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
constant currency financial
"Total revenue grew 3% reported and 2% constant currency, excluding China grew 6%"
Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.
In Vitro Diagnostics pricing medical
"slower sales in China, primarily related to recently announced changes to In Vitro Diagnostics pricing"
non-GAAP financial measures financial
"This press release contains financial measures that are considered non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Earnings Snapshot
Total revenue: $630.9 million · Guidance included
Second quarter ended June 28, 2026
Total revenue
$630.9 million
2.8% increase versus $613.9 million in Q2 2025
GAAP net loss
$92.9 million
compared with $255.4 million net loss in Q2 2025
Adjusted EBITDA
$129.3 million
compared with $106.8 million in Q2 2025
Adjusted diluted EPS
$0.13
compared with $0.12 in Q2 2025
Guidance
Updated 2026 guidance: total revenues $2.52–$2.60 billion, adjusted EBITDA $540–$560 million, adjusted diluted EPS $0.65–$0.90; prior ranges were $2.70–$2.75 billion, $615–$630 million and $1.80–$2.00, respectively, and free cash flow guidance of $100–$120 million was withdrawn.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were QuidelOrtho (QDEL) revenues and earnings for Q2 2026?
QuidelOrtho reported Q2 2026 revenue of $630.9 million and a GAAP net loss of $92.9 million, or $1.36 per diluted share. Adjusted EBITDA was $129.3 million with a 20.5% margin, and adjusted diluted EPS came in at $0.13.
How did QuidelOrtho (QDEL) update its full-year 2026 financial guidance?
QuidelOrtho now guides 2026 revenue to $2.52–$2.60 billion, adjusted EBITDA to $540–$560 million, and adjusted diluted EPS to $0.65–$0.90. Previous ranges were higher, at $2.70–$2.75 billion revenue, $615–$630 million adjusted EBITDA and $1.80–$2.00 adjusted EPS.
How did China affect QuidelOrtho (QDEL) results in Q2 2026?
China revenue declined 18.7% in Q2 2026 to $67.8 million, with a constant currency decline of 23.3%. Labs and Immunohematology in China were pressured, which management linked primarily to recently announced changes to In Vitro Diagnostics pricing in that market.
What were QuidelOrtho (QDEL) segment revenues in Q2 2026?
In Q2 2026, Labs revenue was $382.9 million, Immunohematology revenue was $134.2 million, and Point of Care revenue was $108.2 million. Labs grew 4% as reported, Immunohematology 1%, and Point of Care 16.3%, all versus the prior-year period.
What was QuidelOrtho (QDEL) cash flow and debt position in early 2026?
For the first six months of 2026, QuidelOrtho used $143.6 million in operating cash and $141.3 million in investing activities, while financing provided $238.2 million. At June 28, 2026, cash and equivalents were $123.4 million and long-term borrowings were $2,535.4 million.
Which non-GAAP metrics does QuidelOrtho (QDEL) emphasize for Q2 2026?
QuidelOrtho highlights adjusted EBITDA of $129.3 million and an adjusted EBITDA margin of 20.5%, along with adjusted diluted EPS of $0.13. The company also reports multiple constant currency revenue growth measures and provides detailed reconciliations to the corresponding GAAP figures.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2026
(Exact name of Registrant as specified in its Charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(858 ) 552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
| Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its second quarter ended June 28, 2026 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on August 6, 2026 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
| (d) Exhibits. | ||||||||||||||
| The following exhibit is furnished with this Form 8-K: | ||||||||||||||
| Exhibit Number | Description of Exhibit | |||||||||||||
| 99.1 | Press release, dated August 6, 2026, reporting QuidelOrtho Corporation's financial results for its second quarter ended June 28, 2026. | |||||||||||||
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document. | |||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2026
| QUIDELORTHO CORPORATION | ||||||||
| By: | /s/ MICAH YOUNG | |||||||
| Name: | Micah Young | |||||||
| Its: | Chief Financial Officer | |||||||
Exhibit 99.1
QuidelOrtho Reports Second Quarter 2026 Financial Results
― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth―
― Excluding China, total revenue grew 6% both as reported and in constant currency ―
― Company updates full-year 2026 financial guidance ―
August 6, 2026
SAN DIEGO, CA August 6, 2026 — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026.
Key Second Quarter 2026 Results:
(all comparisons are to the prior year period)
•Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency. Excluding China, total revenue grew 6% both as reported and in constant currency.
◦Labs revenue of $383 million grew by 4% as reported and 2% in constant currency. Growth was driven by continued strength across the core business and partially offset by slower sales in China, which the Company believes is primarily related to recently announced changes to In Vitro Diagnostics pricing. Outside of China, Labs revenue grew 9% both as reported and in constant currency.
◦Immunohematology revenue of $134 million grew 1% both as reported and in constant currency. Outside of China, Immunohematology revenue grew 5% both as reported and in constant currency.
◦Point of Care revenue of $108 million grew 16% both as reported and in constant currency, including Triage revenue growth of 10% as reported and 9% in constant currency.
•GAAP net loss was $93 million; GAAP operating loss was $22 million; adjusted EBITDA was $129 million.
•GAAP net loss margin was 14.7%; GAAP operating loss margin was 3.5%; adjusted EBITDA margin was 20.5%, an improvement of 310 basis points.
•GAAP diluted loss per share was $1.36; adjusted diluted earnings per share (“EPS”) was $0.13.
“Our second quarter performance demonstrated QuidelOrtho’s underlying strength and the benefits of our diversified portfolio, with solid results across our core franchises and regions, with the exception of China. Demand headwinds in China related to the proposed IVD pricing guidelines and a softer global respiratory environment are continuing to impact our business,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. “As a result, we are revising our full-year 2026 revenue and earnings guidance to reflect these evolving market dynamics. In addition, we have decided to withdraw free cash flow guidance as we work through the associated impacts on working capital and our mitigation efforts. This decision does not change our commitment to improving cash conversion, which remains our top priority. We remain focused on serving our customers, executing our strategy, strengthening our balance sheet, and building a stronger, more resilient QuidelOrtho.”
Full-year 2026 Financial Guidance
Based on its current business outlook, the Company is updating its full-year financial guidance below:
| Full-year 2026 Financial Guidance | Updated (as of 8/6/2026) | Previous (as of 5/5/2026) | ||||||
| Total revenues (reported) | $2.52 - $2.60 billion | $2.70 - $2.75 billion | ||||||
| Adjusted EBITDA | $540 - $560 million | $615 - $630 million | ||||||
| Adjusted EBITDA margin | 21% - 22% | 23% | ||||||
| Adjusted diluted EPS | $0.65 - $0.90 | $1.80 - $2.00 | ||||||
| Free cash flow | Withdrawn | $100 - $120 million | ||||||
Please see page 8 of the Second Quarter 2026 Financial Results presentation on the “Investor Relations” page of the Company’s website for the full list of assumptions on which the Company’s current 2026 financial guidance is based.
A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non-GAAP Financial Measures."
Conference Call Information
Following the release of financial results, QuidelOrtho will hold a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com. Presentation materials will also be posted to the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at the time of the call. A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website under the “Events & Presentations” section.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “could,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue,” “aim,” “strive,” “seek” or similar words, expressions or the negative of such terms or other
comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho’s non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions proposed by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”), including under Part I, Item 1A, “Risk Factors” of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
Non-GAAP Financial Measures
This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to “constant currency total revenue changes,” “constant currency total revenue changes, excluding China,” “constant currency Labs revenue changes,” “constant currency Labs revenue changes, excluding China,” “constant currency Immunohematology revenue changes,” “constant currency Immunohematology revenue changes, excluding China,” “constant currency Point of Care revenue changes,” “constant currency Triage revenue changes,” “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted diluted EPS” and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
media@QuidelOrtho.com
QuidelOrtho
Consolidated Statements of Loss
(Unaudited)
(In millions, except per share data)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | June 28, 2026 | June 29, 2025 | ||||||||||||||||||||
| Total revenues | $ | 630.9 | $ | 613.9 | $ | 1,250.7 | $ | 1,306.7 | |||||||||||||||
| Cost of sales, excluding amortization of intangibles | 358.0 | 339.0 | 714.0 | 688.5 | |||||||||||||||||||
| Selling, marketing and administrative | 189.7 | 178.0 | 389.0 | 365.0 | |||||||||||||||||||
| Research and development | 48.7 | 45.7 | 93.6 | 98.9 | |||||||||||||||||||
| Amortization of intangible assets | 49.0 | 47.9 | 95.8 | 95.9 | |||||||||||||||||||
| Restructuring, integration and other charges | 6.5 | 178.9 | 10.9 | 195.0 | |||||||||||||||||||
| Other operating expenses | 0.8 | 5.1 | 1.0 | 11.5 | |||||||||||||||||||
| Operating loss | (21.8) | (180.7) | (53.6) | (148.1) | |||||||||||||||||||
| Interest expense, net | 54.7 | 40.5 | 105.8 | 80.5 | |||||||||||||||||||
| Other expense, net | 4.7 | 8.4 | 1.3 | 9.8 | |||||||||||||||||||
| Loss before income taxes | (81.2) | (229.6) | (160.7) | (238.4) | |||||||||||||||||||
| Provision for income taxes | 11.7 | 25.8 | 24.0 | 29.7 | |||||||||||||||||||
| Net loss | $ | (92.9) | $ | (255.4) | $ | (184.7) | $ | (268.1) | |||||||||||||||
| Basic loss per share | $ | (1.36) | $ | (3.77) | $ | (2.71) | $ | (3.97) | |||||||||||||||
| Diluted loss per share | $ | (1.36) | $ | (3.77) | $ | (2.71) | $ | (3.97) | |||||||||||||||
| Weighted-average shares outstanding - basic | 68.3 | 67.7 | 68.2 | 67.6 | |||||||||||||||||||
| Weighted-average shares outstanding - diluted | 68.3 | 67.7 | 68.2 | 67.6 | |||||||||||||||||||
QuidelOrtho
Condensed Consolidated Balance Sheets
(Unaudited)
(In millions)
| June 28, 2026 | December 28, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 123.4 | $ | 169.8 | |||||||
| Accounts receivable, net | 352.0 | 417.0 | |||||||||
| Inventories | 618.9 | 577.6 | |||||||||
| Prepaid expenses and other current assets | 249.9 | 250.5 | |||||||||
| Assets held for sale | 32.4 | 32.4 | |||||||||
| Total current assets | 1,376.6 | 1,447.3 | |||||||||
| Property, plant and equipment, net | 1,338.6 | 1,358.3 | |||||||||
| Right-of-use assets | 155.8 | 155.5 | |||||||||
| Intangible assets, net | 2,678.4 | 2,563.8 | |||||||||
| Other assets | 165.9 | 244.4 | |||||||||
| Total assets | $ | 5,715.3 | $ | 5,769.3 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 236.5 | $ | 279.4 | |||||||
| Accrued payroll and related expenses | 76.8 | 120.3 | |||||||||
| Income tax payable | 14.0 | 11.5 | |||||||||
| Current portion of borrowings | 355.7 | 178.3 | |||||||||
| Other current liabilities | 310.4 | 376.6 | |||||||||
| Total current liabilities | 993.4 | 966.1 | |||||||||
| Operating lease liabilities | 152.5 | 154.4 | |||||||||
| Long-term borrowings | 2,535.4 | 2,471.9 | |||||||||
| Deferred tax liabilities | 122.1 | 90.0 | |||||||||
| Other liabilities | 137.0 | 166.4 | |||||||||
| Total liabilities | 3,940.4 | 3,848.8 | |||||||||
| Total stockholders’ equity | 1,774.9 | 1,920.5 | |||||||||
| Total liabilities and stockholders’ equity | $ | 5,715.3 | $ | 5,769.3 | |||||||
QuidelOrtho
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In millions)
| Six Months Ended | |||||||||||
| June 28, 2026 | June 29, 2025 | ||||||||||
| Cash (used for) provided by operating activities | $ | (143.6) | $ | 18.8 | |||||||
| Cash used for investing activities | (141.3) | (89.2) | |||||||||
| Cash provided by financing activities | 238.2 | 120.9 | |||||||||
| Effect of exchange rates on cash | 0.3 | 2.7 | |||||||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (46.4) | 53.2 | |||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 169.8 | 98.5 | |||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 123.4 | $ | 151.7 | |||||||
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Net Income
(In millions, except per share data; unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
| June 28, 2026 | Diluted EPS | June 29, 2025 | Diluted EPS | June 28, 2026 | Diluted EPS | June 29, 2025 | Diluted EPS | ||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | (92.9) | $ | (1.36) | $ | (255.4) | $ | (3.77) | $ | (184.7) | $ | (2.71) | $ | (268.1) | $ | (3.97) | |||||||||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of intangibles | 49.0 | 47.9 | 95.8 | 95.9 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring, integration and other charges | 6.5 | 178.9 | 10.9 | 195.0 | |||||||||||||||||||||||||||||||||||||||||||
| Amortization of deferred cloud computing implementation costs | 9.2 | 6.8 | 17.2 | 11.1 | |||||||||||||||||||||||||||||||||||||||||||
| Employee compensation charges | 4.5 | — | 10.0 | — | |||||||||||||||||||||||||||||||||||||||||||
| Tax indemnification expense | 3.3 | — | 3.3 | — | |||||||||||||||||||||||||||||||||||||||||||
| Incremental depreciation on PP&E fair value adjustment | 3.2 | 5.4 | 6.5 | 10.6 | |||||||||||||||||||||||||||||||||||||||||||
| Accelerated depreciation | 2.1 | 1.0 | 4.1 | 1.0 | |||||||||||||||||||||||||||||||||||||||||||
| EU medical device regulation transition costs | 0.7 | 0.1 | 1.4 | 0.3 | |||||||||||||||||||||||||||||||||||||||||||
| Loss (gain) on investments | 8.1 | (1.0) | 9.0 | (1.3) | |||||||||||||||||||||||||||||||||||||||||||
| Other adjustments | 6.8 | 0.8 | 11.5 | 2.0 | |||||||||||||||||||||||||||||||||||||||||||
| Income tax impact of adjustments | 8.7 | 23.4 | 21.8 | 11.6 | |||||||||||||||||||||||||||||||||||||||||||
| Adjusted net income | $ | 9.2 | $ | 0.13 | $ | 7.9 | $ | 0.12 | $ | 6.8 | $ | 0.10 | $ | 58.1 | $ | 0.86 | |||||||||||||||||||||||||||||||
| Weighted-average shares outstanding - diluted | 68.6 | 67.9 | 68.5 | 67.9 | |||||||||||||||||||||||||||||||||||||||||||
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA
(In millions, unaudited)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | June 28, 2026 | June 29, 2025 | ||||||||||||||||||||
| Net loss | $ | (92.9) | $ | (255.4) | $ | (184.7) | $ | (268.1) | |||||||||||||||
| Depreciation and amortization | 116.7 | 110.3 | 229.6 | 217.4 | |||||||||||||||||||
| Interest expense, net | 54.7 | 40.5 | 105.8 | 80.5 | |||||||||||||||||||
| Provision for income taxes | 11.7 | 25.8 | 24.0 | 29.7 | |||||||||||||||||||
| Restructuring, integration and other charges | 6.5 | 178.9 | 10.9 | 195.0 | |||||||||||||||||||
| Amortization of deferred cloud computing implementation costs | 9.2 | 6.8 | 17.2 | 11.1 | |||||||||||||||||||
| Employee compensation charges | 4.5 | — | 10.0 | — | |||||||||||||||||||
| Tax indemnification expense | 3.3 | — | 3.3 | — | |||||||||||||||||||
| EU medical device regulation transition costs | 0.7 | 0.1 | 1.4 | 0.3 | |||||||||||||||||||
| Loss (gain) on investments | 8.1 | (1.0) | 9.0 | (1.3) | |||||||||||||||||||
| Other adjustments | 6.8 | 0.8 | 11.5 | 2.0 | |||||||||||||||||||
| Adjusted EBITDA | $ | 129.3 | $ | 106.8 | $ | 238.0 | $ | 266.6 | |||||||||||||||
| Total revenues | $ | 630.9 | $ | 613.9 | $ | 1,250.7 | $ | 1,306.7 | |||||||||||||||
| Adjusted EBITDA margin | 20.5 | % | 17.4 | % | 19.0 | % | 20.4 | % | |||||||||||||||
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Revenues
(In millions, unaudited)
| Three Months Ended | |||||||||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Labs | $ | 382.9 | $ | 369.7 | 3.6 | % | 1.2 | % | 2.4 | % | |||||||||||||||||||
| Immunohematology | 134.2 | 132.3 | 1.4 | % | 0.7 | % | 0.7 | % | |||||||||||||||||||||
| Donor Screening | 4.0 | 13.3 | (69.9) | % | (0.4) | % | (69.5) | % | |||||||||||||||||||||
| Point of Care | 108.2 | 93.0 | 16.3 | % | 0.6 | % | 15.7 | % | |||||||||||||||||||||
| Molecular Diagnostics | 1.6 | 5.6 | (71.4) | % | 0.6 | % | (72.0) | % | |||||||||||||||||||||
| Total revenues | $ | 630.9 | $ | 613.9 | 2.8 | % | 0.9 | % | 1.9 | % | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Total revenues | $ | 630.9 | $ | 613.9 | 2.8 | % | 0.9 | % | 1.9 | % | |||||||||||||||||||
| China revenue | 67.8 | 83.4 | (18.7) | % | 4.6 | % | (23.3) | % | |||||||||||||||||||||
| Total revenues excluding China | $ | 563.1 | $ | 530.5 | 6.1 | % | 0.2 | % | 5.9 | % | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Labs | $ | 382.9 | $ | 369.7 | 3.6 | % | 1.2 | % | 2.4 | % | |||||||||||||||||||
| China Labs | 56.1 | 69.8 | (19.6) | % | 4.6 | % | (24.2) | % | |||||||||||||||||||||
| Total Labs revenues excluding China | $ | 326.8 | $ | 299.9 | 9.0 | % | 0.2 | % | 8.8 | % | |||||||||||||||||||
(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.
| Three Months Ended | |||||||||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Immunohematology | $ | 134.2 | $ | 132.3 | 1.4 | % | 0.7 | % | 0.7 | % | |||||||||||||||||||
| China Immunohematology | 6.7 | 10.8 | (38.0) | % | 3.8 | % | (41.8) | % | |||||||||||||||||||||
| Total Immunohematology revenues excluding China | $ | 127.5 | $ | 121.5 | 4.9 | % | 0.3 | % | 4.6 | % | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||
| June 28, 2026 | June 29, 2025 | % Change | Currency Impact | Constant Currency (a) | |||||||||||||||||||||||||
| Triage | $ | 32.9 | $ | 29.8 | 10.4 | % | 1.5 | % | 8.9 | % | |||||||||||||||||||
| All other | 75.3 | 63.2 | |||||||||||||||||||||||||||
| Point of Care revenue | $ | 108.2 | $ | 93.0 | 16.3 | % | 0.6 | % | 15.7 | % | |||||||||||||||||||
(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.